



SEVO
Bioscience

Rethinking Therapeutic Delivery in Aquaculture Why Feed-Delivered Solutions Is the Next Category in Fish Health

EXECUTIVE SUMMARY

Aquaculture supplies more than half of the seafood consumed globally and continues to grow as demand for sustainable protein increases. Yet disease outbreaks remain one of the most significant operational and economic risks in fish production. Current prevention strategies in many finfish species rely heavily on labor-intensive injection protocols, which are costly, logistically complex, and difficult to scale across large populations.

SEVO Bioscience is building a new category in aquaculture health: scalable, feed-delivered therapeutics, beginning with oral vaccine applications.

At the core of SEVO's approach is a proprietary microalgae-based synthetic biology platform powered by ANKR™, a biological protein stacking system that enables cells to reliably produce and localize high levels of target proteins without compromising cellular function. This platform allows SEVO to design strains capable of delivering therapeutic payloads efficiently through feed.

SEVO is not developing a single product. It is building the infrastructure layer for how therapeutics can be delivered in aquaculture at scale.

THE STRUCTURAL PROBLEM IN AQUACULTURE HEALTH

DISEASE IS NOT A NICHE ISSUE—IT IS SYSTEMIC.

Fish are livestock. Like cattle or poultry, they are susceptible to viral and bacterial disease pressures that can impact survival, yield, and profitability. However, the public perception of fish health often lags behind land-based livestock understanding.

In many production systems, disease management relies on:

- Physical handling and injection
- Labor-intensive vaccination programs
- Cold-chain and timing constraints
- Operational stress placed on fish populations

While injection can be effective early-on, they introduce economic and logistical friction:

- High labor costs
- Fish stress during handling
- Limited practicality in certain production stages
- Reduced flexibility in fast-scaling environments

As aquaculture operations grow and consolidate, this delivery model becomes increasingly strained.

The industry does not lack therapeutic targets.

It lacks scalable delivery systems.



THE OPPORTUNITY: FEED-DELIVERED THERAPEUTICS

In human and terrestrial animal health, therapeutics are delivered in multiple forms: injectable, oral, topical, and more. In aquaculture, however, therapeutic delivery remains largely concentrated in a narrowband of approaches.

This creates a category gap.

Feed-delivered therapeutics represent a much-needed structural shift:

- No manual injection required
- Lower labor intensity
- Reduced fish stress
- Potential for broader population coverage
- Improved operational flexibility
- Enables out-at-sea booster

The shift is not incremental—it is architectural.

To enable this shift, biology must be engineered to produce and present therapeutic proteins efficiently, reliably, and at scale.

That is where SEVO's platform comes in.

THE SEVO PLATFORM: BIOLOGICAL INFRASTRUCTURE

SEVO's core innovation is ANKR™, a biological organizing system integrated into microalgae cells.

A useful analogy:

A warehouse can store items using shelving, with no shelving present items clutter the warehouse and render it disorganized and inefficient. ANKR™ acts like a shelving system within the cell, organizing and localizing proteins, so the system can handle significantly higher loads without breaking down.

In biological terms:

- ANKR™, enables high protein accumulation at a specific location.
- Cells remain functional and metabolically active.
- Production reliability increases.
- Scaling therapeutic proteins becomes practical.

This structured system transforms the cell from a basic producer into a highly optimized therapeutic factory.

From this foundation, SEVO can:

- Build disease-specific strains
- Develop multiple therapeutic programs
- Expand across species and diseases
- Maintain a strong technical platform for growth

The result is not a single vaccine.

It is a repeatable platform for therapeutic design and deployment.



CATEGORY CREATION: MOVING BEYOND INJECTABLES

Creating a new category requires more than technology.

It requires reframing how the market thinks about the problem.

Today, “therapeutics in aquaculture” is often synonymous with injection. That mental model limits innovation and constrains investment thinking.

SEVO's approach reframes the discussion:

From:

“How do we improve injection efficiency?”

To:

“How do we redesign therapeutic delivery entirely?”

Category creation does not happen overnight. It emerges through:

- Demonstration of technical feasibility
- Commercial validation
- Economic advantage
- Strategic partnerships
- Consistent narrative clarity

SEVO's objective is to establish feed-delivered therapeutic biology as a standard, not an exception.

BUSINESS MODEL AND STRATEGIC POSITIONING

SEVO is structured to focus on high-value infrastructure, not downstream commoditized production.

The company's model emphasizes:

- Strain development and IP ownership
- Geographically structured licensing
- Strategic partnerships for scale
- Multi-program pipeline from a single platform

SEVO does not intend to manufacture feed at industrial scale.

It designs the biological engine that partners deploy.

Why Now?

The convergence of:

- Rising seafood demand
- Increased regulatory pressure
- Higher disease frequency in aquaculture
- Advances in synthetic biology
- Sustainability expectations

Creates a timing window for a new therapeutic delivery paradigm.

SEVO is establishing feed-delivered therapeutics as a new standard in aquaculture health.

Not improving injection. Redefining delivery.